Preclinical imaging of Kallikrein related peptidase 2, hK2, in prostate cancer with a radiolabelled monoclonal antibody, 11B6

Oskar Vilhelmsson Timmermand¹, David Ulmert², Susan Evans-Axelsson³, Kim Pettersson⁴, Anders Bjartell³, Hans Lilja^{2,5,6,7}, Sven-Erik Strand^{1,8}, Thuy A. Tran⁸.

¹Dept. of Medical Radiation Physics, Barngatan 2:1, Lund University, S-211 85, Lund, Sweden.

²Department of Surgery (Urology), Memorial Sloan-Kettering Cancer Center, 1275 *York Avenue*, New York, NY 10065, USA.

³Dept. of Clin. Sciences, Div. Urological Cancers, Jan Waldenstroms gata 5, Lund University, S-205 02, Malmö, Sweden

⁴Dept. of Biochemistry and Food Chemistry/Biotechnology, Tykistökatu 6A BioCity, University of Turku, 205 20 Turku 52, Turku, Finland.


⁵Department of Laboratory Medicine and Medicine (GU Oncology), Memorial Sloan-Kettering Cancer Center, 1250 York Avenue, New York, NY 10065, USA.


⁶Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.

⁷Department of Laboratory Medicine, Lund University, University Hospital UMAS, Malmö, Sweden

⁸Lund University Bioimaging Center, Lund University, BMC, Klinikgatan 32, S-222 42, Lund, Sweden

SUPPLEMENTARY DATA





	$k_a (1/Ms) (10^5)$	$k_d (1/s) (10^{-5})$	$K_D(pM)$
A. 11B6	3.77 ± 0.06	1.94±0.08	51.2 ± 21.5
B. DTPA-11B6	1.52 ± 0.11	<1	66.2 ± 4.63

Figure S1. Surface Plasmon Resonance

The binding kinetics of 11B6 and DTPA-11B6 analyzed by a Biacore 2000 Sensorgram of A. 11B6 to hK2, before conjugation and B. DTPA-11B6 to hK2, after conjugation. k_a , k_d and K_D for 11B6 and DTPA-11B6 is displayed below the graphs.